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Reduced association of anti-apoptotic protein Mcl-1 with E3 ligase
Mule increases the stability of Mcl-1 in breast cancer cells
S Pervin*,1,2, A Tran2, L Tran2, R Urman2, M Braga1, G Chaudhuri2,3 and R Singh1,2,3
1Department of Internal Medicine, Charles Drew University of Medicine and Science, 3084 Hawkins Building, 1731 East 120th Street,
Los Angeles, CA 90059, USA; 2Department of Obstetrics and Gynecology, David Geffen School of Medicine at UCLA, 22-115 CHS, 10833 Le Conte
Avenue, Los Angeles, CA 90095-7358, USA; 3Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA, 10833 Le Conte
Avenue, Los Angeles, CA 90095-7358, USA
BACKGROUND: Mechanisms that increase resistance to apoptosis help promote cellular transformation. Cancer cells have deregulated
apoptotic pathways, where increased expression and stability of anti-apoptotic proteins Mcl-1 and Bcl-2 increases resistance to
apoptosis. Pathways that increase the stability of proteins in cancer cells remain poorly understood.
METHODS: Using human mammary epithelial and established breast cancer cell lines, we assessed the mechanisms that increase the
stability of anti-apoptotic proteins in breast cancer cells by caspase assay, western blot, small-inhibitory RNA treatment and
immunoprecipitation.
RESULTS: While breast cancer cells were resistant to de novo inhibition of protein synthesis, a rapid proteosome-mediated degradation
of Mcl-1 and Bcl-2 induced apoptosis in mammary epithelial cells. Although Mule, an E3 ligase that targets Mcl-1 for degradation was
expressed in mammary epithelial and breast cancer cell lines, rapid increase of polyubiquitinated Mcl-1 and Bcl-2 was detected only in
mammary epithelial cells. Only transient formation of the Mule–Mcl-1 complex was detected in breast cancer cells. Downregulation
of pERK1/2 in breast cancer cells reduced Mcl-1 levels and increased Mcl-1/Mule complex.
CONCLUSION: Our findings suggest that reduced Mule/Mcl-1 complex has a significant role in increasing the stability of Mcl-1 in breast
cancer cells and increased resistance to apoptosis.
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Progression of tumourigenesis is dependent upon many factors
including mechanisms that increase resistance to apoptosis.
Cancer cells have developed effective mechanisms to resist various
stress-induced apoptosis (McCubrey et al, 2007; Djeu and Wei,
2009). Evasion of apoptosis by cancer cells differ from normal cell,
which are relatively more sensitive to mitochondria-mediated
apoptosis (Mu¨llauer et al, 2000; Wang et al, 2003; Jetzt et al, 2009).
Bcl-2 family of proteins have a key role in regulating apoptosis,
where the ratio of anti-apoptotic (Bcl-2, Bcl-XL and Mcl-1) and
pro-apoptotic (Bax, Bad and PUMA) members maintain integrity
of the mitochondrial membrane (Kutuk and Letai, 2008). Common
cancers such as breast and prostate express high levels of Bcl-XL
and Bcl-2 proteins, which inhibit mitochondria-mediated apopto-
sis (Nun˜ez et al, 1991; Callagy et al, 2008). In addition to increased
transcription, additional mechanisms that increase stability of
anti-apoptotic proteins in cancer cells remain poorly understood
(Abdelmohsen et al, 2007; Shimazu et al, 2007). Some of the known
mechanisms by which proteins are stabilised in breast cancer cells
are through acetylation, glycosylation or increased association
with various chaperones. In MCF-7 cell line, Raf-1 exists in a
complex with heat shock protein hsp-90 and this complex is
essential for Raf-1 protein stability (Schulte et al, 1995). Another
protein that gets stabilised in breast cancer is AP-2a, a
transcription factor that binds to HER-2/neu gene promoter and
has a half-life of 30 h compared with 1 h in normal cells (Li et al,
2006). This increased stability of AP-2a protein has been found to
induce HER-2 overexpression, which has an adverse prognosis in
10–34% of breast cancers (Pellikainen and Kosma, 2007).
The ubiquitin–proteosome machinery, a common pathway for
protein degradation, has been implicated in regulating protein
stability, cell viability and apoptosis (McBride et al, 2003;
Thompson et al, 2008). Proteins targeted for proteosomal
degradation get polyubiquitinated at specific lysine residues
through a multistep process mediated by E1, E2 and E3 ligases.
The ubiquitination mechanism consists of three steps: (1)
activation of ubiquitin (ub) monomers by E1 ligase, (2) transfer
of activated ub from E1 ligase to E2 ligase and (3) transfer of the ub
polymers from E2 ligase to the protein targeted for degradation by
E3 ligase. An ubiquitin chain forming a specific lysine– lysine
linkage serves as a signal for degradation of proteins (Sun, 2006;
Petroski, 2008). Poorly understood aberrations in the ubiquitin–
proteosome machinery could increase stability of anti-apoptotic
proteins in breast cancer cells. We used cycloheximide (CHX) to
inhibit de novo protein synthesis and investigated mechanisms
that increase the stability of anti-apoptotic proteins in breast
cancer cells. We find that CHX treatment promotes mitochondria-
mediated apoptosis through decline in levels of Mcl-1 and Bcl-2 in
normal mammary epithelial cells. In breast cancer cells, reduced
ubiquitination and degradation of Mcl-1 and Bcl-2 was detectedRevised 9 May 2011; accepted 3 June 2011; published online 5 July 2011
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with CHX treatment. We demonstrate that unstable binding of
Mcl-1 with E3 ligase Mule could be one of the prominent
mechanisms that increases stability of Mcl-1 in breast cancer cells.
MATERIALS AND METHODS
Cell culture
Human breast cancer cell lines MDA-MB-231, MDA-MB-468 and
MCF-7 were obtained from American Type Culture Collection
(Manassas, VA, USA). These cells were cultured in DMEM
containing 10mM non-essential amino acids, 2mM L-glutamine,
10 gml–1 insulin and 10% fetal bovine serum. MCF-10A, a
spontaneously immortalised untransformed human mammary
epithelial cell line was obtained from Robert J Pauley (Barbara
Ann Karmanos Cancer Institute, Detroit, MI, USA). HMLE, a
human mammary epithelial cell line immortalised by the
introduction of SV40 large-T oncogene and hTERT was obtained
from Professor Robert Weinberg (Whitehead Institute at MIT,
Cambridge, MA, USA). MCF-10A and HMLE were cultured in
DMEM: Ham’s F-12 (1 : 1) supplemented with 5% equine serum,
10mM HEPES, 10 mgml–1 insulin, 20 ngml–1 epidermal growth
factor, 100 ngml– 1 cholera enterotoxin and 0.5 mgml–1 hydro-
cortisone (Pervin et al, 2003).
Chemicals
Antibodies used were from the following suppliers: rabbit
polyclonal anti-Ub (G0805), anti-Mcl-1 from Santa Cruz Biotech
Inc. (Santa Cruz, CA, USA); rabbit polyclonal anti-Mule (A300-
486A; Bethyl Laboratories, Montgomery, TX, USA), mouse anti-
HRF from BD Biosciences Pharmingen (San Diego, CA, USA);
rabbit anti-Puma from Abcam (Boston, MA, USA); rabbit
polyclonal anti-caspase-3 (65906E), mouse monoclonal anti-
cytochrome c (65981A) and rabbit polyclonal ERK1/2 MAP kinase
(9102) from New England Biolabs (Ipswich, MA, USA); mouse
monoclonal anti-Bcl-2 (Ab-1) from Calbiochem (La Jolla, CA,
USA). Cycloheximide and MG132 were obtained from Sigma
(St Louis, MO, USA).
TUNEL assay
The TUNEL assay was performed using ApoAlert DNA Fragmen-
tation Assay Kit from Clontech (Palo Alto, CA, USA). Cells
(3 106) were collected by centrifugation and washed twice with
PBS. Cells were fixed in 1% formaldehyde-PBS at 41C for 20min
and incubated with nucleotide mixture and terminal deoxynucleo-
tidyl transferase enzyme for analysis in a Becton Dickinson Flow
Cytometer (Singh et al, 2000).
Caspase assay
Cells were lysed in insect cell lysis buffer containing 50mM HEPES,
100mM NaCl, 2mM EDTA, 0.1% 3-((3-cholamidopropyl) dimethy-
lammonio)-1-propanesulfonic acid (CHAPS), 10% sucrose, 5mM
DTT and 1 protease inhibitor for 30min at 41C. The lysates were
used for caspase-3 (30 mg) and caspase-9 (50 mg) enzymatic assays
using respective substrates. The cleaved fluorescent substrate was
quantified using a Versa Fluro flurometer (Bio-Rad, Hercules, CA,
USA), with excitation at 380 nm and emission at 440 nm (Pervin
et al, 2007).
Cell fractionation and cytochrome c detection
Cytochrome c release into the cytosol was detected as described
previously with minor modifications (Pervin et al, 2003; Pervin
et al, 2007). Briefly, 6 106 cells were harvested and washed with
PBS. The cells were suspended in buffer A (20mM HEPES-KOH
(pH 7.5), 10mM KCl, 1.5mM MgCl2, 1mM EDTA, 1mM EGTA, 1mM
DTT, 250mM sucrose and 1 protease inhibitor cocktail) and
were homogenised by Dounce homogeniser; unbroken cells and
nuclei were removed by centrifugation at 1000 g for 20min. The
cytosolic fraction was analysed by western blot with an anti-
cytochrome c monoclonal antibody (7H8 2C12) or with an anti-
GAPDH antibody (Pervin et al, 2003, 2007).
Western analysis
Cells were lysed in cell lysis buffer (50mM HEPES, pH 7.5; 1mM
DTT, 150mM NaCl, 1mM EDTA, 0.1% Tween 20, 10% glycerol,
10mM a-glycerophosphate, 1mM NaF, 0.1mM orthovanadate,
10 mgml–1 leupeptin, 10 mgml–1 aprotinin and 0.1mM PMSF)
and incubated at 41C for 30min for analysis of cytosolic proteins.
Lysates (100mg) were resolved electrophoretically on 4–15%
gradient SDS–polyacrylamide gel and electro transferred to a
polyvinylidine difluoride membrane (Bio-Rad) using a tank blot
procedure (Bio-Rad Mini Protean II). The membranes were
incubated with various primary antibodies (1 : 1000 dilution) and
respective horseradish peroxidase-linked secondary antibody
(1 : 1000 dilution) (Amersham Corp., Piscataway, NJ, USA) for
1 h. Immunoreactive bands were visualised by ECL detection
system (Amersham) (Singh et al, 2000; Pervin et al, 2003, 2007).
Immunoprecipitation
Cells were lysed in lysis buffer containing 50mM Tris/HCl, pH 8.0,
300mM NaCl, 10mM MgCl2, 0.5% Igepal Ca-630 (Sigma), 1mM
EDTA and anti-protease cocktail (Roche, San Francisco, CA, USA).
Supernatant (500mg) were pre-cleared by incubation (4 h at 41C)
once with Protein A/G-agarose (Santa Cruz Biotechnology) and
once with Protein A/G-agarose pre-incubated with pre-immune
serum. The pre-cleared lysate was adjusted to 150mM NaCl and
0.25% Igepal Ca-630 and subjected to overnight immunoprecipita-
tion with the respective antibodies. The mixtures were incubated
further for 4 h at 41C with 50 ml of Protein A/G-agarose and
processed for western blot analysis (Pervin et al, 2007).
Small-interfering (siRNA) transfection
Breast cancer cells were propagated into six-well plates at 2 105
cells per well, grown for 24 h in complete medium followed by
transfection with ON-TARGET plus Smart pool siRNA specific to
Puma, HRF and Mcl-1 (Dharmacon, Chicago, IL, USA) or
scrambled siRNA-negative control at a final concentration of
20 nM using lipofectamine reagent. Mule siRNA sequence (50-AAU
UGCUAUGUCUCUGGGACA-30) used to target human Mule was
designed as described before (Chen et al, 2005; Parsons et al,
2009). Efficiency of transfection was monitored by analysing the
cell lysates after 3 days of transfection by western blot analysis
using respective antibodies (Pervin et al, 2007). siRNA transected
cells were further subjected to vehicle or CHX treatment for
various time points, lysed and analysed by western blot analysis or
enzymatic assay for caspase-3.
Statistical analysis
Data are presented as mean±s.e.m. Student’s t-test was performed
for comparison between two groups. For statistical analysis
of more than two groups, data were analysed by ANOVA,
and pairwise comparisons were performed by Tukey’s posttest
procedure. P-values o0.05 were considered statistically
significant.
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RESULTS
Resistance of breast cancer cells to CHX-induced apoptosis
We initially performed S35 methionine uptake assays to determine
the concentrations and duration of CHX treatment required to
inhibit protein synthesis in both mammary epithelial and breast
cancer cells. Significant inhibition of protein synthesis was
observed within 6 h of CHX treatment in the normal mammary
epithelial cells (100 mgml–1 CHX) and breast cancer cells
(200mgml–1 CHX) (Figure 1A). Only in mammary epithelial cells,
CHX treatment induced DNA fragmentation and cell death as
detected by TUNEL assay and trypan blue exclusion method,
respectively (Figure 1B). We next examined caspase-3, an
executioner caspase in the apoptotic cascade that commits cells
to apoptosis by inducing DNA fragmentation along with other
prominent changes. Caspase-3 activity, measured using DEVD-
AMC as a substrate, significantly increased in CHX-treated
(6–16 h) MCF-10A and HMLE cells, while no activity was detected
in breast cancer cells (Figure 1C). We also examined the activation
of caspase-9, which functions upstream of caspase-3, by using
Ac-LEHD-AMC as substrate. Caspase-9 activities followed the
similar pattern as caspase-3 and increased 5–6 folds at 16 h only in
CHX-treated MCF-10A and HMLE cells, while no significant
increased activity was detected in breast cancer cells (Figure 1D).
Breast cancer cell lines became cytostatic with CHX treatment at
24 h and no significant increase in caspase-3/9 activities or
apoptosis was detected at 16 h (Figures 1B–D) or even 24–48 h
(data not shown). Cytostatic cells were viable even until 72 h of
CHX treatment as assessed by trypan blue exclusion assay and
no TUNEL-positive cells were detected in that time frame (data
not shown).
To determine whether CHX-induced increase in caspase-3 and
caspase-9 activities were mitochondria dependent in normal
mammary epithelial cells, the cells were fractionated and the
cytosolic fractions were analysed for an increase in cytochrome c
levels by western blot analysis. We found increased cytochrome c
levels at 16 h in the cytoplasm of CHX-treated MCF-10A and
HMLE cells, confirming the involvement of mitochondria-
mediated apoptotic pathway (Figure 1E). No increase in cytosolic
cytochrome c was found in breast cancer cells even at 48 h of CHX
treatment (data not shown). Our data therefore indicate that
de novo inhibition of protein synthesis induces mitochondria-
mediated apoptosis only in normal mammary epithelial cells, while
breast cancer cells were resistant to this treatment.
Reduced ubiquitination and increased stability
of anti-apoptotic proteins in cancer cells
Since CHX treatment increased cytosolic cytochrome c in MCF-
10A and HMLE cells, we examined the stability of Mcl-1 and Bcl-2
proteins that maintain the integrity of mitochondrial membrane.
The stability of anti-apoptotic proteins Mcl-1 and Bcl-2 was also
assessed in these MDA-MB-468, MDA-MB-231 and MCF-7 breast
cancer cells after treatment with CHX (200 mgml–1). Mcl-1 levels
were reduced in CHX-treated MCF-10A (52±6%) and HMLE
(62±6%) cells at 3 h (Figure 2A, left panel); whereas, Bcl-2 levels
were reduced by 66±7% in MCF-10A and 48±6% in HMLE cells
after similar treatments at 16 h as assessed by western blot analysis
(Figure 2A, right panel). No significant decline in the levels of Mcl-
1 and Bcl-2 was observed in the cancer cell lines where the overall
levels remained relatively stable and even increased at 16–24 h of
CHX treatment (Figure 2A, left and right panels). The decline in
Mcl-1 and Bcl-2 in CHX-treated normal cells was further
confirmed by immunoprecipitation assays. Mcl-1 and Bcl-2 were
immunoprecipitated with Mcl-1 or Bcl-2 antibodies from CHX-
treated lysates, which were further immunoblotted with their
respective antibodies. Immunoprecipitation analysis confirmed
that the decline in Mcl-1 (Figure 2B, left panel) and Bcl-2 (data not
shown) was only in CHX-treated normal mammary epithelial
cells but not in the CHX-treated breast cancer cells (Figure 2B,
right panel).
We next examined the mechanism(s) that promote selective
decline of Mcl-1 and Bcl-2 only in MCF-10A and HMLE cells.
To determine whether the ubiquitination of Mcl-1 and Bcl-2
increased with CHX treatment, the cell lysates at various time
points were immunoprecipitated with ubiquitin antibody and
immunoblotted for Mcl-1. We found increased levels of
ubiquitinated Mcl-1 in CHX-treated MCF-10A at 16–24 h
(Figure 2C, left panel), while in MDA-MB-468 cells, no prominent
ubiquitination of Mcl-1 was detected (Figure 2C, right panel).
Similar results were obtained when total cellular ubiquitinated
proteins were immunoprecipitated and immunoblotted with Bcl-2.
Ubiquitinated Bcl-2 was found only in CHX-treated MCF-10A
cells but not in MDA-MB-231 cells (data not shown).
To further determine whether ubiquitinated Mcl-1 and Bcl-2 in
normal mammary epithelial cells were degraded through the 26S
proteosomal complex, a chemical inhibitor of the proteosomal
machinery, MG132 was used. The stability of Bcl-2 and Mcl-1
proteins was examined by western blotting in cells pre-incubated
with MG132 for 2 h followed by CHX treatment. Treatment with
MG132 inhibitor completely attenuated the decline of Mcl-1 in
CHX-treated human mammary epithelial cells, confirming the
involvement of the 26S proteasomal degradation pathway
(Figure 3A). However, CHX-induced decline of Bcl-2 levels was
only partially attenuated with MG132 treatment in the normal
mammary epithelial cells (Figure 3A). Our data, therefore, may
suggest that MG132 selectively inhibits CHX-induced degradation
of Mcl-1 but Bcl-2 degradation in response to CHX may not be
entirely dependent on proteasomal pathways in mammary
epithelial cells. Pre-treatment with the inhibitor MG132 followed
by CHX exposure resulted in no significant change in the Mcl-1 or
Bcl-2 levels in the breast cancer cell lines MDA-MB-231
(Figure 3A), MDA-MB-468 and MCF-7 (data not shown). Pre-
treatment with the inhibitor, MG132, also attenuated the CHX-
induced dramatic increase in caspase-3 activity in MCF-10A cells
(Figure 3B, left panel). On the other hand, in breast cancer cells, no
significant change in caspase-3 activity was observed with or
without MG132 pre-treatment followed by CHX exposure
(Figure 3B, right panel). Furthermore, we detected higher levels
of polyubiquitinated proteins that accumulate without degradation
in MG132-treated MCF-10A but not in MDA-MB-468 cells
(Figure 3C). Therefore, our results indicate that inhibition of
protein synthesis in MCF-10A and HMLE cells increases rapid
degradation of Mcl-1 and to some extent Bcl-2 by ubiquitin–
proteosome machinery.
Reduced association of Mcl-1 with Mule in breast cancer
cells
We next examined the key players or mechanisms that increased
the ubiquitination and degradation of Mcl-1 and Bcl-2 in
mammary epithelial cells as well as their aberrations in breast
cancer cells. E3 ligase, which targets proteins for degradation, has
been characterised for Mcl-1 but not for Bcl-2. We examined the
expression of Mule, the specific E3 ligase for Mcl-1 by western blot
analysis in both the normal mammary epithelial and breast cancer
cells. Mule was constitutively expressed in normal mammary
epithelial and breast cancer cells (in some breast cancer cell lines
Mule was induced by CHX treatment). The protein level of Mule
was also comparable between MCF-10A and MDA-MB-468 cells,
while it was induced in MDA-MB-231 cells at 6–16 h of CHX
treatment (Figure 4A). The mRNA expression of Mule as
determined by real-time qPCR in all the cell lines were examined,
which followed similar pattern as that of the proteins (data
not shown).
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Figure 1 Resistance of breast cancer cells to cycloheximide (CHX) treatment. (A) MCF-10A and MDA-MB-468 cells treated with 100–200 mgml –1 of
CHX for 6 or 16 h were harvested following 4 h of incubation with S35 Met/Cys. The cells were lysed and S35 Met/Cys incorporation into proteins was
examined. (B) (Left panel) Cells treated with CHX (200 mgml –1) for 16 h and DNA fragmentation was assessed by TUNEL assay. (Right panel) Cells
treated with CHX (200mgml– 1) for 16 h and cell viability was assessed by trypan blue assay, white open bar (0 h); black closed bar (16 h). (C) Cells treated
with CHX (200mgml– 1) for 6 and 16 h were lysed and 30mg of the lysate was subjected to fluorometric assay for caspase-3 activity. (D) Cells treated with
CHX (200 mgml –1) for 6 and 16 h were lysed and 50mg lysates were subjected to fluorometric assay for caspase-9 activity. (E) MCF-10A and HMLE cells
were treated with CHX (200 mgml –1) for various time points (0–24 h) and subjected to mitochondria and cytosolic fractionation. Western blot analysis was
performed using 100 mg of cytosolic fraction using cytochrome c antibody. Data represent mean±s.e.m. of four independent experiments in triplicates
(asterisks denote statistically significant values compared with untreated control group, *Pp0.05 and **Pp0.01).
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Since ubiquitination of Mcl-1 was reduced in breast cancer cells
even though Mule was constitutively expressed or induced by
CHX, we examined the association of Mcl-1 and Mule by
immunoprecipitation assays. Mule was immunoprecipitated from
CHX-treated cell lysates of MCF-10A and MCF-7 cells and
immunoblotted with Mcl-1 antibody. In MCF-10A and HMLE
cells, we found increased Mcl-1 and Mule complex between 6–24 h
of CHX treatment (Figure 4B, left panel). We also performed
immunoprecipitation of CHX-treated MCF-10A and MCF-7 cells
by Mule followed by western blotting with anti-Bcl-2 antibody. We
did not find any significant association of Mule with Bcl-2 in MCF-
10A cells (Figure 4B, bottom panel) or in MCF-7 cells (data not
shown). We also confirmed this prolonged association between
Mule and Mcl-1 in CHX-treated normal mammary epithelial cells
by immunoprecipitating Mcl-1 and blotting for Mule (Figure 4C,
left panel). However, in all the breast cancer cell lines examined,
we were unable to detect any prolonged association of Mcl-1 and
Mule between 0 and 36 h of CHX treatment. In MDA-MB-468 cells,
we could detect only transient association of Mcl-1 and Mule at
12–16 h, and at each of these time points where the complex was
detected, there was a sharp decline in Mule–Mcl-1 complex
(Figure 4B, right panel). In MCF-7 cells, we could detect
association between Mcl-1 and Mule only at 12 h (Figure 4C, right
panel); while in MDA-MB-231 cells, very weak association was
detected at 24 and 48 h (data not shown). Our results indicate that
unstable association between Mule and Mcl-1 may contribute to
decreased ubiquitination and degradation of Mcl-1 in breast
cancer cells. We were unable to detect significant association of
another known E3 ligase b-TrCP with Mcl-1 in either normal
mammary epithelial or breast cancer cells (data not shown).
In order to further investigate the role of Mule during CHX-
induced apoptosis in normal mammary epithelial cells, we
downregulated Mule expression by siRNA. HMLE and MCF-10A
cells treated with either random siRNA or Mule siRNA were
incubated with CHX (200 mgml– 1) and apoptotic index was
analysed by TUNEL assay. We found that inhibition of Mule
levels in these cells by siRNA treatment significantly decreased
their apoptotic index (HMLE: 61±5%; MCF-10A: 66±3%)
(Figure 4D).
CHX regulation of Mcl-1-binding proteins Puma and HRF
Puma and HRF (translationally controlled tumour protein) are
known to interact with Mcl-1 and increase the stability of Mcl-1.
Accordingly, we initially examined the stability of Mcl-1 associat-
ing proteins in CHX-treated mammary epithelial and breast cancer
cells. Puma (Figure 5A) and HRF (Figure 5C) levels declined with
CHX treatment in MCF-10A cells. In most of the CHX-treated
breast cancer cell lines, we found increased stability of Mcl-1
associating proteins Puma (Figure 5A, left panel) and HRF
(Figure 5C). We further examined the association of Puma, and
HRF with Mcl-1 by immunoprecipitating each of these proteins
and western blotting for Mcl-1. Since Puma levels declined in
CHX-treated MCF-10A cells, we further examined the effects of
CHX on Puma–Mcl-1 complexes by immunoprecipitating total
cytosolic Puma and immunoblotting for Mcl-1. We found Puma
associated with Mcl-1 in control MCF-10A cells but the complex
was reduced in CHX-treated cells (Figure 5A, right panel). In both
control and CHX-treated MDA-MB-468 cells, Puma–Mcl-1 com-
plex remained stable (Figure 5A, right panel). To examine whether
a decline in Puma could promote Mcl-1 ubiquitination and
degradation, we downregulated Puma in breast cancer cell lines
with Puma siRNA and examined Mcl-1–Mule complex. Puma
levels reduced by 70% in MDA-MB-468 cells treated with Puma
siRNA compared to those treated with scrambled controls
(Figure 5B, left panel). A decline in Puma levels did not increase
Mcl-1–Mule complex (data not shown) or ubiquitination of Mcl-1
as assessed by immunoprecipitation and western analysis in breast
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Figure 2 Reduced ubiquitination and increased stability of Mcl-1 and Bcl-2 in breast cancer cells treated with CHX (200 mgml – 1). (A) Cells treated with
CHX for various time points and cell lysates (100 mg) were subjected to western blot analysis for Mcl-1 and GAPDH (left panel) and Bcl-2 and GAPDH
(right panel) proteins. (B) CHX-treated cell lysates (500 mg) from MCF-10A (left panel) and MDA-MB-231 (right panel) were subjected to
immunoprecipitation with anti-Mcl-1 antibody and immunoblotted for Mcl-1. (C) CHX-treated cell lysates (500mg) from MCF-10A (left panel) and MDA-
MB-231 (right panel) were subjected to immunoprecipitation with anti-Ub antibody and immunoblotted for Mcl-1.
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cancer cells (Figure 5B, right panel). While the levels of HRF
declined with CHX treatment in MCF-10A, its level did not change
in MDA-MB-231 cells. However, MDA-MB-468 cells behaved
similar to normal mammary cells in response to CHX
(Figure 5C, left panel). We also downregulated Mcl-1-associated
HRF in breast cancer cell lines MDA-MB-231 with HRF siRNA
(Figure 5C, middle panel) and found a moderate increase in
ubiquitination of Mcl-1 levels (Figure 5C, right panel).
Downregulation of pERK1/2 increased Mcl-1–Mule
complex in breast cancer cells
It has been shown that ERK1/2 can phosphorylate and stabilise
Mcl-1 in breast cancer cells (Ding et al, 2008). We found ERK1/2
and its active form pERK1/2 upregulated in all the breast cancer
cells examined and their levels remain unchanged with CHX
treatment, indicating increased stability of these proteins
(Figure 6A). Inactivation of pERK1/2 with MEK inhibitor U0 126
(data not shown) or nitric oxide donor DETA-NONOate promoted
the decline of Mcl-1 levels in breast cancer cell line MDA-MB-468
(Figure 6A). Downregulation of pERK1/2 by treatment with MEK
inhibitor or nitric oxide donor also increased Mule–Mcl-1
(Figure 6B, left panel) complex and caspase-3 activity in breast
cancer cells, indicating induction of apoptosis (Figure 6C, right
panel). However, MEK1/2 inhibitor or nitric oxide induced delay
and lower caspase-3 activity in cells compared with higher caspase-3
activation when Mcl-1 was downregulated by Mcl-1 siRNA
(Figure 6C, right panel). These results indicate that HRF and
ERK1/2 partially increased the stability of Mcl-1 in breast cancer
cells. It is possible that additional mechanisms operate in breast
cancer cells that increase stability of Mcl-1 and resistance to
apoptosis.
DISCUSSION
In this study, we found that increased stability of anti-apoptotic
proteins like Mcl-1 and Bcl-2 rendered breast cancer cells resistant
to CHX-induced apoptosis. However, in mammary epithelial
(MCF-10A, HMLE) cells, CHX treatment increased degradation
of Mcl-1 through the ubiquitin-dependent proteosomal pathway to
induce apoptosis. We show that downregulation of Mcl-1 by Mcl-1
siRNA or inhibiting ERK1/2 through U0126 or nitric oxide
treatment increased the sensitivity of breast cancer cells to CHX-
induced apoptosis. Our result is consistent with a number of
studies which show that drugs like flavopiridol, lipoxygenase
inhibitors and roscovitine downregulated both Mcl-1 and Bcl-2 in
breast cancer cells, while okadaic acid and immunotoxins among
others specifically downregulated only Mcl-1 to induce apoptosis
(Rieber et al, 2002; Tong et al, 2002; Wittmann et al, 2003;
Andersson et al, 2004; Ortiz-Ferro´n et al, 2008).
We found reduced ubiquitination of Mcl-1 and unstable
association of Mcl-1 with its specific E3 ligase Mule in breast
cancer cells treated with CHX. To our knowledge, this is the first
report that has found transient association between Mule and Mcl-1
in breast cancer cells. Mule is a novel ubiquitin that contains
domain homologous to E6-AP carboxyl terminus (HECT) as well as
Bcl-2 homology region (BH3) domain that allows Mule to specifically
interact with Mcl-1 (Warr et al, 2005; Zhong et al, 2005). We were
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able to detect a stable prolonged association between Mcl-1–Mule in
CHX-treated MCF-10A cells, where Mcl-1 undergoes prominent
ubiquitination and degradation.
Mcl-1 is stabilised by HRF, which serves as Mcl-1 chaperone and
prevents its proteasomal degradation (Liu et al, 2005). Mcl-1
associating protein Puma (p53 upregulated modulator of
apoptosis) also increases Mcl-1 stability, but does not ultimately
prevent Mcl-1 degradation since its PEST (praline, glutamic acid,
serine and threonine) region is still exposed (Mei et al, 2005). Mcl-
1 also interacts with tankyrase-1, which promotes telomere
elongation in human cells, and its overexpression inhibits the
activity of Mcl-1L and Mcl-1S (Bae et al, 2003). In our study,
downregulation of Puma did not decrease Mcl-1 levels or increase
CHX-mediated apoptosis in breast cancer cells. We did find
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downregulating HRF in breast cancer cells increased Mcl-1
ubiquitination and apoptosis; however, higher apoptosis induction
was observed when Mcl-1 was directly downregulated by Mcl-1
siRNA or indirectly by downregulating pERK1/2. This suggests that
mechanisms other than Mcl-1 associating proteins could be operating
in breast cancer cells leading to increased stability of Mcl-1.
Although we found that reduced 26S proteosomal degradation of
key anti-apoptotic proteins increases survival of breast cancer
cells, highly selective potent inhibitors of this machinery is
emerging as promising new anti-tumour agents (Cardoso et al,
2004; Sterz et al, 2008). The rational that promoted this therapeutic
approach was that increased stabilisation of Rpn4, a transcription
activator of proteasome genes, severely reduced cell viability under
stressed conditions. Rpn4, in addition to being a major mediator of
core Rpn4-proteosome feedback circuit also appears to be a major
mediator in a stress response network (Xie, 2010). Bortezomib, a
proteasome inhibitor, has been shown to have some beneficial
effect of in reducing proliferation and metastatic potential of
aggressive breast cancer cell lines in in vitro and in vivo model
(Jones et al, 2010). However, this compound, which is also the only
FDA-approved proteasome inhibitor in clinical use, has shown
limited clinical activity against metastatic breast cancer in patients
(Yang et al, 2006). Bortezomib, however, has proven effective
against some haematologic malignancies like lymphoma where it
decreases proliferation, induces apoptosis and enhances sensitivity
to various chemotherapy and radiation treatments (Ludwig et al,
2005; Cavo, 2007). Lack of effectiveness of proteosome inhibitors
against breast cancer warranted using it in combination with
standard cytotoxic agents including docetaxel. A clinical trial using
Bortezomib and docetaxel combination as treatment regimen
against malignant breast cancer in patients has shown very limited
clinical efficacy (Awada et al, 2008). Our current findings may
suggest that increasing 26S proteosome-mediated degradation of
Mcl-1 might have therapeutic benefits in inducing apoptosis in
breast cancer cells (Figure 6D).
Since we found transient association between Mcl-1 and Mule in
cancer cells, in addition to HRF and pERK1/2 we are examining
deubiquitinating enzymes (DUBs) that function downstream in
ubiquitin pathways and have the potential to be the final editors of
protein ubiquitination status and thus determine substrate fate
(Millard and Wood, 2006). In several studies, DUBs have been
implicated in regulating the stability of several proteins and can
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and 100 mg of cell lysates were subjected to immunoblot analysis using anti-Puma antibody. (Right panel) Cells treated with CHX for various time points
(0–16 h) were immunoprecipitated for Puma and immunoblotted with anti- Mcl-1 antibody. (B) MDA-MB-468 cells treated with scrambled (Ran siRNA) or
HRF siRNA was immunoblotted for Puma and GAPDH (left panel), or immunoprecipitated with ubiquitin (Ub) antibody and blotted for Mcl-1 (right panel).
(C) (Left panel) Cells treated with CHX (200 mgml – 1) for various time points (0–16 h) and 100 mg of cell lysates were subjected to immunoblot analysis
using anti-HRF antibody. (Middle panel) MDA-MB-231 cells treated with scrambled (Ran siRNA) or HRF siRNA and immunoblotted using anti-HRF
antibody. (Right panel) Cells treated with HRF siRNA (HR si) or with HRFsiþCHX (200 mgml –1) were immunoprecipitated with Mcl-1 antibody and
immunoblotted using anti-Ub antibody.
Stability of anti-apoptotic proteins in breast cancer
S Pervin et al
435
British Journal of Cancer (2011) 105(3), 428 – 437& 2011 Cancer Research UK
M
o
le
c
u
la
r
D
ia
g
n
o
st
ic
s
extend the half-life of proteins destined for proteasomal degrada-
tion by catalysing hydrolysis of isopeptide bond in ubiquitin
protein conjugates (Graner et al, 2004; Sheng et al, 2006; Pereg
et al, 2010). Some of these DUBs are overexpressed in breast
cancer (McFarlane et al, 2010).
Few studies have correlated increased stability of proteins with
oncogenicity or tumour progression. Signalling cascades in cancer
cells that increase resistance to apoptosis has been targeted to
control tumourigenesis. Our finding of increased stability of Mcl-1
in breast cancer cells due to reduction of Mcl-1–Mule complex
introduces new players that can be targeted for therapeutic
interventions to induce apoptosis in breast cancer. Further studies
focusing on better understanding of deubiquitination–ubiquitin
cycle’s role are needed to develop new therapeutic targets for
breast cancer therapy.
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